Global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Growth (Status and Outlook) 2023-2029

Global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Growth (Status and Outlook) 2023-2029

ADHD is a brain/neurodevelopmental/neurobehavioral disorder characterized by pervasive and impairing symptoms of inattention, hyperactivity, and impulsivity. The Centers for Disease Control and Prevention (CDC) defines “neurobehavioral” as the way the brain affects emotion, behavior, and learning.

LPI (LP Information)' newest research report, the “Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Industry Forecast” looks at past sales and reviews total world Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics sales in 2022, providing a comprehensive analysis by region and market sector of projected Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics sales for 2023 through 2029. With Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics industry.

This Insight Report provides a comprehensive analysis of the global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics.

The global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.

Growth in the ADHD therapeutics market is mainly driven by granular impact of changing lifestyles and value systems impacting quality of births, increasing use of additives and preservations in children’s diet, rising prevalence of ADHD among children in the 4–17 year age group, increasing adoption of diagnostic guidelines (statistical manual of mental disorders) with low threshold for diagnosis of ADHD in other regions such as Europe and Latin America. Moreover, increasing awareness regarding ADHD among physicians and patients, and opinion-based diagnosis of ADHD owing to lack of standard diagnostic tests is expected to boost revenue growth of the global ADHD therapeutics market in the near future. However, existence of comorbid conditions in children leads to underdiagnoses of ADHD and less availability of non-stimulants ADHD drugs in various geographies. These are factors expected to restrain growth of the market over the forecast period.

This report presents a comprehensive overview, market shares, and growth opportunities of Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
Stimulants
Non-Stimulants

Segmentation by application
Specialty Clinics
Hospital Pharmacies
Retail Pharmacies
E-Commerce

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Eli Lilly and Company
Novartis
Takeda
Pfizer
GlaxoSmithKline
Mallinckrodt Pharmaceuticals
Hisamitsu Pharmaceutical
Impax Laboratories
Johnson ＆Johnson
UCB
Purdue Parma

Please note: The report will take approximately 2 business days to prepare and deliver.